Drs van Toorenenbergen, Beishuizen, de Groot and Oranje are part of the Working Group on Childhood Mastocytosis.
Serum tryptase and SCORMA (SCORing MAstocytosis) Index as disease severity parameters in childhood and adult cutaneous mastocytosis
Version of Record online: 10 DEC 2008
© 2008 The Author(s). Journal compilation © 2008 British Association of Dermatologists
Clinical and Experimental Dermatology
Volume 34, Issue 4, pages 462–468, June 2009
How to Cite
Heide, R., Van Doorn, K., Mulder, P. G., Van Toorenenbergen, A. W., Beishuizen, A., De Groot, H., Tank, B. and Oranje, A. P. (2009), Serum tryptase and SCORMA (SCORing MAstocytosis) Index as disease severity parameters in childhood and adult cutaneous mastocytosis. Clinical and Experimental Dermatology, 34: 462–468. doi: 10.1111/j.1365-2230.2008.03005.x
Conflict of interest: none declared.
- Issue online: 12 MAY 2009
- Version of Record online: 10 DEC 2008
- Accepted for publication 23 June 2008
Background. Skin lesions are the predominant clinical feature of the commonest form of mastocytosis. Mastocytosis is classified according to World Health Organization criteria. Determination of the levels of mast-cell mediators or their metabolites reflects the mast-cell burden. The extent of cutaneous mastocytosis can be assessed clinically using a scoring system (SCORing MAstocytosis; SCORMA Index) that we have developed.
Objective. Serum tryptase levels were compared with the SCORMA Index in a large group of paediatric and adult patients to investigate whether there was any correlation between the two.
Methods. The SCORMA Index in 64 patients (31 children and 33 adults) was compared with serum tryptase levels. The results of the first visit at which SCORMA and tryptase were evaluated were analysed.
Results. There was a positive correlation between the SCORMA Index and serum tryptase levels, indicating the value of the SCORMA Index in the assessment of mastocytosis with skin involvement.
Conclusion. The results of this study showed that the SCORMA Index is a useful tool for evaluating the severity of cutaneous mastocytosis. The correlation between the SCORMA Index and serum tryptase levels underlines the benefit of the SCORMA Index as a clinical tool. Repeated SCORMA Index measurements can provide a rapid impression of changes in the clinical state of mastocytosis. This is particularly relevant in children, because taking blood samples from this group is much more difficult. The well-established methods for evaluation of disease severity may be expanded by the rapid SCORMA Index method.